Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.48 |
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.47 |
| ▸ | CYP27B1 | O15528 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129271 | 0.96 | CYP24A1 (0.52) | SMN1; SMN2CYP19A1CYP24A1CYP27B1 | |
| SCHEMBL6571604 | 0.70 | SMN1; SMN2 (0.84) | SMN1; SMN2CYP19A1 | |
| SCHEMBL10852854 | 0.69 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP24A1CYP27B1 | |
| SCHEMBL331966 | 0.69 | CYP19A1 (0.90) | SMN1; SMN2CYP19A1 | |
| SCHEMBL11486009 | 0.69 | CYP19A1 (0.47) | CYP19A1 | |
| SCHEMBL9715141 | 0.68 | SMN1; SMN2 (0.77) | SMN1; SMN2 | |
| SCHEMBL3895572 | 0.68 | SMN1; SMN2 (0.58) | SMN1; SMN2 | |
| SCHEMBL10860461 | 0.68 | CYP19A1 (0.46) | CYP19A1CYP24A1CYP27B1 | |
| SCHEMBL7126453 | 0.67 | MAPT (0.54) | SMN1; SMN2CYP24A1CYP27B1 | |
| SCHEMBL7126449 | 0.66 | CYP24A1 (0.94) | CYP24A1CYP27B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002045704-A2 | PREVENTION AND TREATMENT OF TACHYPHYLACTIC RESPONSE | MOLECULAR SKINCARE LIMITED (GB) | 2002-06-13 | — | — | WO | claimed |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-31 | — | — | US | disclosed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-7846957-B2 | Aromatase inhibition to enhance assisted reproduction | ARES TRADING S.A. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| US-20080045484-A1 | Use of Aromatase Inhibitors for Endometrial Thinning in Preparation for Surgical Procedures on the Endometrial Cavity and Uterus | MOUNT SINAI HOSPITAL (CA) | 2008-02-21 | — | — | US | disclosed |
| US-20080025991-A1 | Use of Aromatase Inhibitors for Treatment of Ectopic Pregnancy | MOUNT SINAI HOSPITAL (CA) | 2008-01-31 | — | — | US | disclosed |
| US-20040171660-A1 | Single dose aromatase inhibitor for treating infertility | ARES TRADINS S.A. (CH) | 2004-09-02 | — | — | US | disclosed |
| WO-2002083240-A9 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING SA (CH) | 2004-05-06 | — | — | WO | disclosed |
| EP-1381431-A1 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING S.A. (CH) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003082254-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AROMATASE INHIBITOR AND AN ESTROGEN SUITABLE FOR HORMONE REPLACEMENT THERAPY FOR A MALE | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082299-A1 | IMPROVED HORMONE REPLACEMENT THERAPY | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082336-A1 | FEMALE BIRTH CONTROL METHOD | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003045381-A1 | AMINOALKYLIMIDAZOLE DERIVATIVES AND THEIR USE IN MEDICINE | MOLECULAR SKINCARE LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002083240-A1 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002045704-A2 | PREVENTION AND TREATMENT OF TACHYPHYLACTIC RESPONSE | MOLECULAR SKINCARE LIMITED (GB) | 2002-06-13 | — | — | WO | disclosed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045484-A1 | Use of Aromatase Inhibitors for Endometrial Thinning in Preparation for Surgical Procedures on the Endometrial Cavity and Uterus | CYP19A1, SHBG, HSD17B11 | SMN1; SMN2 4398/4885CYP19A1 1/4885CYP24A1 305/4885 |
| US-20080025991-A1 | Use of Aromatase Inhibitors for Treatment of Ectopic Pregnancy | CYP19A1, HSD17B11, CYP17A1 | SMN1; SMN2 4688/4885CYP19A1 1/4885CYP24A1 250/4885 |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | SMN1; SMN2 2780/4885CYP19A1 1/4885CYP24A1 90/4885 |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | ESR1, ESR2, ESRRA | SMN1; SMN2 2390/4885CYP19A1 7/4885CYP24A1 269/4885 |
| US-20040171660-A1 | Single dose aromatase inhibitor for treating infertility | CYP19A1, FSHR, SHBG | SMN1; SMN2 4730/4885CYP19A1 1/4885CYP24A1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.